Thermo Fisher: Great Business Still Trading At A Risky Price Before Earnings (NYSE:TMO)

Thermo Fisher Scientific (TMO) is a high-quality business but is currently overvalued given its growth outlook. With FY25 revenue growth of 3.9% and EPS growth of 7.3%, and a FY26 adjusted EPS growth guidance of 6-8%, the stock’s near 30x earnings/free cash flow valuation seems stretched without a return to double-digit growth. The author maintains a Hold rating, citing fair-to-rich valuation and potential risks like funding pressures and macroeconomic instability.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin